Literature DB >> 28143786

Compliance with vaccination against tick-borne encephalitis virus in Germany.

L Jacob1, K Kostev2.   

Abstract

OBJECTIVES: The goal of this study was to analyse patients' compliance with vaccination against tick-borne encephalitis (TBE) virus in Germany.
METHODS: The present study included 7266 patients from 638 general practices and 4194 patients from 114 paediatric practices. Patients were included if they had received the first dose of one of two vaccines against TBE virus (FSME-Immune® and Encepur®). The immunization schedule of these vaccines consisted of three injections. Patients were considered compliant if they received the second and third doses at the recommended time or within a period of ±25% around the recommended time (tolerance period).
RESULTS: Of the recruited patients, 28% received both the second and the third injections within the tolerance period. Individuals treated in paediatric practices had a higher likelihood of receiving vaccine doses within the tolerance period compared with individuals treated in general practices (OR 2.15; 95% CI 1.92-2.41). Moreover, patients <18 years old were more likely to be compliant than patients >65 years old (OR 1.22; 95% CI 1.02-1.46), whereas patients aged between 18 and 30 years were least likely to be compliant (OR 0·77; 95% CI 0.61-0.96).
CONCLUSIONS: Compliance with vaccination against the TBE virus was low. This compliance was significantly associated with age and the type of practices in which patients were treated.
Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Germany; compliance; risk factors; tick-borne encephalitis virus; vaccination

Mesh:

Substances:

Year:  2017        PMID: 28143786     DOI: 10.1016/j.cmi.2017.01.012

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients.

Authors:  Nicole Harrison; Katharina Grabmeier-Pfistershammer; Alexandra Graf; Ilse Schwarzinger; Judith H Aberle; Karin Stiasny; Hildegard Greinix; Werner Rabitsch; Peter Kalhs; Michael Ramharter; Heinz Burgmann; Christina Forstner
Journal:  NPJ Vaccines       Date:  2020-07-24       Impact factor: 7.344

2.  Tick-borne encephalitis in Europe, 2012 to 2016.

Authors:  Julien Beauté; Gianfranco Spiteri; Eva Warns-Petit; Hervé Zeller
Journal:  Euro Surveill       Date:  2018-11

3.  Completion of multiple-dose travel vaccine series and the availability of pharmacist immunizers: A retrospective analysis of administrative data in Alberta, Canada.

Authors:  Sherilyn K D Houle; Dean T Eurich
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

4.  A cross-sectional study evaluating tick-borne encephalitis vaccine uptake and timeliness among adults in Switzerland.

Authors:  Kyra D Zens; Vasiliki Baroutsou; Philipp Sinniger; Phung Lang
Journal:  PLoS One       Date:  2021-12-14       Impact factor: 3.240

5.  Prevalence and treatment of sexually transmitted infections in men followed by urologists in Germany - a cross sectional study with 347,090 men.

Authors:  Louis Jacob; Dragos Andrei Duse; Karel Kostev
Journal:  Ger Med Sci       Date:  2018-08-13

6.  Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: A retrospective study of 954,186 patients.

Authors:  Louis Jacob; Mara John; Matthias Kalder; Karel Kostev
Journal:  Curr Med Mycol       Date:  2018-03

7.  Rhombencephalitis and Myeloradiculitis Caused by a European Subtype of Tick-Borne Encephalitis Virus.

Authors:  Lorna Neill; Anna M Checkley; Laura A Benjamin; M Trent Herdman; Daniel P Carter; Steven T Pullan; Emma Aarons; Katie Griffiths; Bernadette Monaghan; Kushan Karunaratne; Olga Ciccarelli; Jennifer Spillane; David A J Moore; Dimitri M Kullmann
Journal:  Emerg Infect Dis       Date:  2019-12       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.